ClinicalTrials.gg
RecruitingNCT06981325CEMI-firstUpdated Nov 5, 2026

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

A Phase 2 interventional study of Cemiplimab in Basal Cell Carcinoma (BCC) and First Line Treatment, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 8 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 5, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Carcinoma, Basal Cell with a site in Germany — 7 open to participants now, 8 under way, none of them phase 3. Carcinoma, Basal Cell · Germany.

Planned enrollment
18th of 22
34 · median 106
Started
2025
with 1 other
Phase 2
11 of 31
4 open now
Registered
27th of 31
by date

Among the 31 studies in Carcinoma, Basal Cell with a site in Germany, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 in phase 2, and was the 27th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

7 of the 31 studies in Carcinoma, Basal Cell with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Carcinoma, Basal Cell with a site in Germany, or all of them as a file.
02

Study summary

The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).

Read the detailed description

The present study is an explorative, investigator-initatied, single-arm, multicentre phase II trial. Patients with locally advanced BCC without pretreatment with hedgehog inhibitors such as vismodegib and sonidegib will receive Cemiplimab (350 mg, i.v.) at day 1 of each 21 days cycle for up to 12 months (max. 17 cycles) or until intolerable toxicity or disease progression, whatever occurs first. All patients will be followed up until death or for up to 12 months after last patient last application of Cemiplimab. The treatment response will be assessed every 12 weeks (± 7 days) during the treatment and the follow up phase. In addition, tumor samples will be collected and used for translational research providing the basis for the establishment of potential biomarkers correlating with the efficacy of Cemiplimab. The primary objective of this study is to evaluate the efficacy of Cemiplimab when applied as first-line treatment in advanced, HHI naïve BCC measured by objective response rate (ORR) after 6 months of treatment. Secondary objective is to evaluate the safety and tolerability of Cemiplimab as first-line treatment in advanced BCC.

03

Conditions studied

  • Basal Cell Carcinoma (BCC)
  • First Line Treatment

Keywords

  • BCC
  • Skin Cancer
  • Basal Cell Carcinoma
  • anti-PD-1 monoclonal antibody
  • HHI naïve
  • Cemiplimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form available
  2. Patient* 18 years or older at time of signing informed consent form
  3. Centrally confirmed histological diagnosis of BCC

    NOTE: Tumor tissue to be sent to Central Pathology during screening procedure:

    • Formalin-fixed, parrafin-embedded (FFPE) tumor specimen in a paraffin block (preferred) OR
    • approximately 10 sections (5µm thickness) on uncoated slides and 10 sections (5µm thickness) on Superfrost Ultra slides containing unstained, freshly cut, serial sections to be submitted along with associated pathology report (please refer to section 11.1.1 for details)
  4. Locally advanced stage without distant , not amenable for surgery or radiotherapy or surgery/radiotherapy or refused by patient (as evidenced in source data)
  5. Expected survival of at least 6 months
  6. performance status 0 or 1
  7. Adequate laboratory parameters particularly for the blood count, renal and liver function parameters.

    1. Absolute number of neutrophils ≥ 1.5 x 109/L
    2. ≥ 75 x 109/L
    3. ≥ 9 g/dL
    4. Total ≤ 1.5 times the (ULN), (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
    5. (SGOT) and ALT (SGPT) ≤ 3x ULN
    6. AP ≤ 2.5x ULN
    7. Serum creatinine ≤ 2x ULN or ≥ 40 mL/min
  8. Absence of other severe comorbidities
  9. Resolution of any acute, treatment-related adverse events from prior therapy/procedure to Grade ≤ 1 prior to study entry, with the exception of alopecia.
  10. Negative serum pregnancy test done less than or equal to 7 days prior to enrollment, for females of only.
  11. Sexually active women of childbearing potential (WOCBP) and men with WOCBP partners must be prepared to use suitable method with a failure rate of \< 1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab

    • There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently

Exclusion criteria

Exclusion Criteria:

  1. Pretreatment with systemic immunotherapy (such as /PD-L1 or CTL4) or targeted therapy (such as hedgehog inhibitor) NOTE: Prior treatment with imiquimod or other topical or intralesional immune modulators will not be exclusionary
  2. Any other non-radiation anti-cancer therapy (e.g. imiquimod, photodynamic therapy; neither nor standard of care) within 30 days (from date of last administration) of initial Cemiplimab administration or if planned during the study duration
  3. Ongoing or recent (within 5 years) evidence of significant disease that required systemic therapy, excluding: vitiligo, childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism requiring only hormone replacement, or psoriasis that does not require systemic treatment
  4. Other neoplasia, in particular hematologic diseases that might impair immune response, such as chronic lymphocytic leukemia, myelodysplastic or myeloproliferative disease and patients with Gorlin-Goltz syndrom
  5. Immunosuppressive doses (> 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of Cemiplimab NOTE: Patients who require brief courses of steroids (e.g., as prophylaxis for imaging studies due to to contrast agents) are eligible for participation. Furthermore, patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or replacement in case of adrenal or hypophysis insufficiency are eligible for participation.
  6. Known allergic/hypersensitive reaction to the study drug and any of its or history of documented allergic/hypersensitive reactions to antibody treatments
  7. Active infection requiring systemic therapy, including uncontrolled , and infection or diagnosis of immunodeficiency.

    NOTE: Patients are eligible if:

    • Patients have controlled HIV infection with is > 350 cells/µL and viral load is undectable [HIV RNA PCR]
    • Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undectable serum viral load [HBV DNA PCR]. Patients must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab
    • Patients positive for HCV antibody have controlled HCV infection with undectable viral load [HCV RNA PCR]
  8. History of pneumonitis within the last 3 years
  9. Patients with history of solid organ transplant (patients with prior corneal transplants may be allowed to enroll after discussion with and approval from the Lead Investigator)
  10. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  11. Receipt of (including attenuated) within 30 days of first administration of Cemiplimab
  12. Pregnancy or lactation period.
  13. Medical or psychological conditions that would not permit the patient to complete the study or sign .
  14. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  15. Legal incapacity or limited legal capacity.
  16. On-treatment participation in another clinical trial in the period 30 days prior to start of the study treatment and during the study
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Cemiplimab - Single Arm

    Single Arm with Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for up to 12 months (max. 17 cycles).

    Drug: Cemiplimab

Interventions

  • Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for up to 12 months (max. 17 cycles).

    Also known as: LIBTAYO

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) at six months

    ORR@6months, defined as the rate of patients assessed with complete or partial response (CR or PR) according to ERIVANCE-like criteria as best overall response, relative to the total number of patients as evaluated 6 months after treatment allocation.

    Time frame: 24 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    rate of patients assessed with complete or partial response (CR or PR) as best overall response, relative to the total number of patients.

    Time frame: 42 months

  2. Progression Free Survival (PFS)

    time from date of allocation to treatment to the date of the first objectively documented tumor progression, as determined by investigators, or death due to any cause.

    Time frame: 42 months

  3. Duration of Response (DoR)

    length of time from initial response (CR/PR) to first objectively documented progression or death.

    Time frame: 42 months

  4. Overall Survival (OS)

    time from date of allocation to treatment until the date of death from any cause

    Time frame: 42 months

  5. Time to next systemic treatment (TTNsT)

    time from date of allocation to treatment to initiation of the next line of systemic therapy

    Time frame: 42 months

  6. Safety (AEs and SAEs)

    Incidence of adverse events and serious adverse events

    Time frame: 42 months

  7. AE severity

    Severity of adverse events by CTCAE v5.0 grade

    Time frame: 42 months

  8. Safety (AEs)

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 42 months

Other outcomes

  1. Determination of molecular biomarkers and their correlation with objective response rate (ORR)

    Biosamples will be used for determination of molecular biomarkers and their correlation with objective response rate (ORR) by assessing e.g., gene expression signatures, tumor mutational burden including mutational signatures as well as morphological and cellular characteristics of the tumor microenvironment.

    Time frame: 42 months

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No IPD will be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2028, 38 months after the start.

Of 44 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
May 20, 2025
StartActual
Aug 7, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Jul 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Universitätsklinikum Regensburg · Regensburg, Germany
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    1 site added
    Show site
    • Universitätsklinikum Regensburg · Regensburg, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06981325
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Skin Cancer Center Minden, Department of Dermatology, Johannes-Wesling-Klinikum Minden, Universität Duisburg-Essen, Regeneron Pharmaceuticals
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Aug 7, 2025
Primary completion
Oct 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Ralf Gutzmer, Prof. Dr. med.
Contact
Ralf.Gutzmer@Muehlenkreiskliniken.de
+49 571/ 790 4501
Michelle Tez
Contact
tez.michelle@ikf-khnw.de
+4969 / 5899 787 65
Salah-Eddin Al-Batran, Prof. Dr. med.
study director · Institut für Klinische Krebsforschung IKF GmbH
Ralf Gutzmer, Prof. Dr. med.
principal investigator · Johannes Wesling Klinikum Minden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion